Want to see HAE full AI Analyst Report?
HAE Stock Chart & Stats
$78.78
$1.13(1.43%)
At close: 4:00 PM EDT
$78.78
$1.13(1.43%)
Day’s Range― - ―
52-Week Range$47.32 - $87.32
Previous Close$79.91
Volume803.18K
Average Volume (3M)720.82K
Market Cap
$3.89B
Enterprise Value$3.53K
Total Cash (Recent Filing)$245.44M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)41.9
Beta0.49
Next Earnings
Aug 06, 2026EPS Estimate
1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.04
Shares Outstanding45,445,984
10 Day Avg. Volume569,544
30 Day Avg. Volume720,821
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)3.20
Price to Sales (P/S)1.91
P/FCF Ratio9.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$80.57Price Target Upside2.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)5.22
Revenue Forecast (FY)$1.40B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables / Installed-base ModelHaemonetics’ installed-base business—selling equipment then proprietary disposables—creates predictable, recurring per-procedure revenue and strong customer lock-in. This durable stream supports revenue visibility, margin stability and cross-sell of services and software over multi-year device lifecycles.
Robust Cash Generation And ConversionSustained operating cash flow and high FCF conversion demonstrate earnings quality and self-funding capacity. Strong cash generation supports product investment, targeted tuck-ins, buybacks and deleveraging, reducing dependence on external financing and enhancing long-term strategic flexibility.
Regulatory Approvals And Portfolio ExpansionRecent regulatory clearances and product rollouts expand clinical use cases and addressable markets in plasma and hospital hemostasis. These durable approvals and acquisitions can drive device placements and attached consumable demand, strengthening competitive position and long-term revenue mix.
Bears Say
Elevated LeverageHigher leverage reduces financial flexibility and increases sensitivity to interest-rate moves, constraining capital allocation. With net leverage elevated post-refinancing (~2.7x EBITDA per disclosures), debt servicing limits room for aggressive M&A or large buybacks and raises refinancing and covenant risk over the medium term.
Recent Margin And Earnings CompressionThe sharp decline in net margin and modest revenue contraction indicate profit conversion weakness despite healthy gross margins. Sustained margin recovery is required to restore returns on equity and cash flow per share; failure would pressure reinvestment capacity and investor confidence over several quarters.
Acquisition Dilution And Structural Cost HeadwindsNear-term dilution from Vivasure plus higher tariff, tax and interest assumptions will pressure adjusted EPS and free cash flow conversion. Integration costs and delayed revenue realization increase execution risk and extend the time horizon before acquisitions and investments contribute positively to margins and ROE.
Haemonetics News
HAE FAQ
What was Haemonetics’s price range in the past 12 months?
Haemonetics lowest stock price was $47.31 and its highest was $87.32 in the past 12 months.
What is Haemonetics’s market cap?
Haemonetics’s market cap is $3.89B.
When is Haemonetics’s upcoming earnings report date?
Haemonetics’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Haemonetics’s earnings last quarter?
Haemonetics released its earnings results on May 07, 2026. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.273 by $0.017.
Is Haemonetics overvalued?
According to Wall Street analysts Haemonetics’s price is currently Undervalued.
Does Haemonetics pay dividends?
Haemonetics does not currently pay dividends.
What is Haemonetics’s EPS estimate?
Haemonetics’s EPS estimate is 1.08.
How many shares outstanding does Haemonetics have?
Haemonetics has 45,445,984 shares outstanding.
What happened to Haemonetics’s price movement after its last earnings report?
Haemonetics reported an EPS of $1.29 in its last earnings report, beating expectations of $1.273. Following the earnings report the stock price went up 3.228%.
Which hedge fund is a major shareholder of Haemonetics?
Currently, no hedge funds are holding shares in HAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haemonetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$80.57 (2.27% Upside)
$80.57 (2.27% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 71.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.24%
Trailing 12-Months
Company Description
Haemonetics
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
HAE Company Deck
HAE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong achievements: solid organic revenue growth (notably in plasma and blood management), full-year margin expansion, robust free cash flow and disciplined capital allocation, plus important product approvals and commercialization progress (Persona PLUS, VASCADE MVP XL and Vivasure acquisition). Notable near-term headwinds were acknowledged, including a weak interventional technologies performance, Q4 margin pressure driven by tariffs and transition effects, Vivasure dilution, and higher tax/interest costs. Management provided constructive FY2027 guidance (revenue growth and margin expansion), emphasized most large portfolio transitions are behind them, and outlined clear commercialization and launch plans. Overall, the positive operational and financial momentum and confident guidance outweigh the manageable near-term challenges.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$80.57
▲(2.27% Upside)
Technical Analysis
Ownership Overview
1.83% Insiders
38.45% Mutual Funds
7.83% Other Institutional Investors
23.53% Public Companies and
Individual Investors